Verastem price to sales ratio VSTM

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 10.4×
7-year median: 9.9×
Against its 7-year history: 51st; percentile: 0 is its lowest day, 100 its highest
7-year range: 2.7× to 185×
Peer median: 1.7×

Verastem's price to sales ratio is 10.4× as of Oct 23, 2026.

That is above its 7-year median of 9.9×, close to the middle of its last 7 years.

Over that time it ranged from 2.7× in Nov 2020 to 185× in Dec 2021.

The median for 10 large drugmakers of a similar size is 1.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.4×	6.6×	10.7×
2025	n/m a value too high to mean anything
2024	n/m a value too high to mean anything
2023	72.0×	26.1×	78.1×
2022	26.8×	18.5×	171×
2021	185×	3.6×	185×
2020	3.9×	2.7×	35.1×
2019	6.9×	3.3×	6.9×

Against its peers

Companies in Drug Manufacturers - General nearest Verastem's size, closest first, today.

Company	Price to sales ratio
VSTMVerastem	10.4×
ABUSArbutus Biopharma	4.6×
AMPHAmphastar Pharmaceuticals	1.5×
COLLCollegium Pharmaceutical	0.9×
OMEROmeros	n/m
CRMDCorMedix	1.3×
ZVRAZevra Therapeutics	4.3×
IRWDIronwood Pharmaceuticals	1.5×
PCRXPacira BioSciences	1.9×
PBYIPuma Biotechnology	2.5×
ANABAnaptysbio	n/m
Peer median	1.7×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Verastem

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.